{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:11Z","timestamp":1791828551701,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T00:00:00Z","timestamp":1520208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s13365-018-0615-7","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T11:42:14Z","timestamp":1520250134000},"page":"323-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event"],"prefix":"10.1007","volume":"24","author":[{"given":"Joseph R.","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineeta","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Lacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brunetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia B.","family":"Lehane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,5]]},"reference":[{"key":"615_CR1","unstructured":"(2014) Rituxan (rituximab) injection, for intravenous use [package insert]. South San Francisco: Genentech, Inc."},{"key":"615_CR2","unstructured":"(2016) MabThera (rituximab) [summary of product characteristics]. Grenzach-Wyhlen, Germany: Roche Pharma AG; Welwyn Garden City: Roche Registration Limited"},{"key":"615_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jns.2015.04.010","volume":"353","author":"F Asztely","year":"2015","unstructured":"Asztely F, Gilland E, Wattjes MP, Lycke J (2015) Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis. J Neurol Sci 353:155\u2013157","journal-title":"J Neurol Sci"},{"key":"615_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","volume":"12","author":"JR Berger","year":"2017","unstructured":"Berger JR (2017) Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 12:59\u201363","journal-title":"Mult Scler Relat Disord"},{"key":"615_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.25034","volume":"62","author":"CO Bingham 3rd","year":"2010","unstructured":"Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C et al (2010) Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 62:64\u201374","journal-title":"Arthritis Rheum"},{"key":"615_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.semarthrit.2015.06.003","volume":"45","author":"D Borie","year":"2015","unstructured":"Borie D, Kremer JM (2015) Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis. Semin Arthritis Rheum 45:163\u2013166","journal-title":"Semin Arthritis Rheum"},{"key":"615_CR7","unstructured":"(2007) Rituxan warning. FDA Consumer 41:3."},{"key":"615_CR8","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymore JF et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 113:4834\u20134840","journal-title":"Blood"},{"key":"615_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s13365-014-0303-1","volume":"21","author":"S Chahin","year":"2015","unstructured":"Chahin S, Berger JR (2015) A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy. J Neurovirol 21:623\u2013631","journal-title":"J Neurovirol"},{"key":"615_CR10","unstructured":"CIOMS (1995) Report of CIOMS (Council of International Organizations of Medical Sciences) Working Group III. Guidelines for Preparing Core Clinical-Safety Information on Drugs, Geneva"},{"key":"615_CR11","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","volume":"68","author":"DB Clifford","year":"2011","unstructured":"Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D et al (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68:1156\u20131164","journal-title":"Arch Neurol"},{"key":"615_CR12","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793\u20132806","journal-title":"Arthritis Rheum"},{"key":"615_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3389\/fimmu.2015.00241","volume":"6","author":"D Durali","year":"2015","unstructured":"Durali D, de Go\u00ebr de Herve MG, Gasnault J, Taoufik Y (2015) B cells and progressive multifocal leukoencephalopathy: search for the missing link. Front Immunol 6:241","journal-title":"Front Immunol"},{"key":"615_CR14","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572\u20132581","journal-title":"N Engl J Med"},{"key":"615_CR15","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390\u201312400","journal-title":"Arthritis Rheum"},{"key":"615_CR16","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ et al (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab\u2019s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69:1629\u20131635","journal-title":"Ann Rheum Dis"},{"key":"615_CR17","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1002\/art.24906","volume":"60","author":"RM Fleischmann","year":"2009","unstructured":"Fleischmann RM (2009) Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 60:3225\u20133228","journal-title":"Arthritis Rheum"},{"key":"615_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jns.2007.12.015","volume":"268","author":"Y Hashi","year":"2008","unstructured":"Hashi Y, Kimura A, Kato S, Koumura A, Sakurai T, Tanaka Y et al (2008) Progressive multifocal leukoencephalopathy and CD4+ T-lymphocytopenia in a patient with Sjogren syndrome. J Neurol Sci 268:195\u2013198","journal-title":"J Neurol Sci"},{"key":"615_CR19","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"E Keystone","year":"2007","unstructured":"Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J et al (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56:3896\u20133908","journal-title":"Arthritis Rheum"},{"key":"615_CR20","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1128\/JVI.75.7.3483-3487.2001","volume":"75","author":"IJ Koralnik","year":"2001","unstructured":"Koralnik IJ, Du Pasquier RA, Letvin NL (2001) JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 75:3483\u20133487","journal-title":"J Virol"},{"key":"615_CR21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54:613\u2013620","journal-title":"Arthritis Rheum"},{"key":"615_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","volume":"57","author":"P Lee","year":"2013","unstructured":"Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S et al (2013) A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virology 57:141\u2013146","journal-title":"J Clin Virology"},{"key":"615_CR23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3899\/jrheum.090442","volume":"37","author":"PJ Mease","year":"2010","unstructured":"Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M et al (2010) Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 37:917\u2013927","journal-title":"J Rheumatol"},{"key":"615_CR24","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1002\/art.34468","volume":"64","author":"ES Molloy","year":"2012","unstructured":"Molloy ES, Calabrese LH (2012) Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 64:3043\u20133051","journal-title":"Arthritis Rheum"},{"key":"615_CR25","unstructured":"Prosperini L, Scarpazza C, Imberti L, De Rossi N, Cordioli C, Capra R, Italian PML Study Group (2016) Age at natalizumab start as risk cofactor for developing early onset progressive multifocal leukoencephalopathy. European Committe for Treatment and Research in Multiple Sclerosis; September 14\u201317; London, UK [abstract P1598]. \n                    http:\/\/onlinelibrary.ectrims-congress.eu\/ectrims\/2016\/32nd\/146026\/luca.prosperini.3Cb3Eage.at.natalizumab.start.as.risk.cofactor.for.developing.html?f=m2\n                    \n                  ."},{"key":"615_CR26","unstructured":"Roche (2015) Data on file. Drug Safety Report No1066994: Progressive Multifocal Leukoencephalopathy (PML) Cumulative Update Report for Rituximab (MabThera\/ Rituxan)"},{"key":"615_CR27","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","volume":"49","author":"A Rubbert-Roth","year":"2010","unstructured":"Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carre\u00f1o L, Armstrong G et al (2010) Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 49:1683\u20131693","journal-title":"Rheumatology (Oxford)"},{"key":"615_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221\u2013232","journal-title":"N Engl J Med"},{"key":"615_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/ard.2010.137703","volume":"70","author":"PP Tak","year":"2011","unstructured":"Tak PP, Rigby WF, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W et al (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70:39\u201346","journal-title":"Ann Rheum Dis"},{"key":"615_CR30","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF Vollenhoven van","year":"2013","unstructured":"van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann RM, Furst DE et al (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72:1496\u20131502","journal-title":"Ann Rheum Dis"},{"key":"615_CR31","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF Vollenhoven van","year":"2015","unstructured":"van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB (2015) Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol 42:1761\u20131766","journal-title":"J Rheumatol"},{"key":"615_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ana.24371","volume":"77","author":"HS Wollebo","year":"2015","unstructured":"Wollebo HS, White MK, Gordon J, Berger JR, Khalili K (2015) Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol 77:560\u2013570","journal-title":"Ann Neurol"}],"updated-by":[{"DOI":"10.1007\/s13365-018-0637-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,4,10]],"date-time":"2018-04-10T00:00:00Z","timestamp":1523318400000}}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-018-0615-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-018-0615-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-018-0615-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T21:47:14Z","timestamp":1551736034000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-018-0615-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1007\/s13365-018-0615-7","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,5]]},"assertion":[{"value":"30 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2018","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article \u201cProgressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event,\u201d written by Joseph R. Berger, Vineeta Malik, Stuart Lacey, Paul Brunetta, and Patricia B. Lehane\n                      \n                      , was originally published electronically on the publisher\u2019s internet portal (currently SpringerLink).","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All studies were previously reported and were in compliance with the Helsinki Declaration; local institutional review board approval was given at each participating site.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Joseph R. Berger has received personal fees as a consultant to Genentech and Roche. He reports grants from Biogen, during the conduct of the study; personal fees from Amgen; personal fees from Astra-Zeneca; personal fees from Janssen; personal fees from Millennium\/Takeda; personal fees from Novartis; personal fees from Biogen; personal fees from Genzyme\/Sanofi; personal fees from Inhibikase; personal fees from Forward Pharma; personal fees from Johnson and Johnson; personal fees from Pfizer; and personal fees from Eisai, outside the submitted work.Vineeta Malik was an employee of Roche at the time of this study.Stuart Lacey is an employee of Roche.Paul Brunetta was an employee of Genentech at the time of this study.Patricia Lehane is an employee of Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}